论文部分内容阅读
目的:探讨黛力新合硫酸吗啡控释片治疗晚期癌性疼痛效果。方法:选取2010.8-2017.5我院收治的60例晚期癌症患者,按照随机原则,将其分为研究组和对照组,每组患者30例,对照组患者采取硫酸吗啡控释片治疗,研究组患者采取黛力新合硫酸吗啡控释片治疗,对比两组患者的疼痛控制情况。结果:研究组患者癌性疼痛得到明显控制,其疼痛程度明显低于对照组(P<0.05);两组患者治疗前HAMD评分无明显差异(P>0.05),经治疗,研究组患者HAMD评分明显优于对照组(P<0.05)。结论:黛力新合硫酸吗啡控释片治疗晚期癌症,可有效控制疼痛,促使患者较为舒适的度过生存期,尽可能延长患者的生存期,提升患者的满意度,值得临床上大范围推广应用。
OBJECTIVE: To investigate the efficacy of olisulfide morphine sulfate controlled release tablets in the treatment of advanced cancer pain. METHODS: Sixty advanced cancer patients admitted to our hospital from 2010.8 to 2017.5 were randomly divided into a study group and a control group. 30 patients in each group were treated with morphine sulfate controlled release tablets. Patients in the control group were treated with controlled-release morphine sulfate tablets. We took control of morphine sulfate and controlled release tablets to compare the pain control of the two groups. Results: The cancer pain in the study group was significantly controlled and the pain was significantly lower than that in the control group (P<0.05). There was no significant difference in the HAMD score between the two groups before treatment (P>0.05). After treatment, the HAMD score was obtained in the study group. It was significantly better than the control group (P<0.05). Conclusion: Philip morphine sulfate controlled release tablets for the treatment of advanced cancer, can effectively control the pain, make patients more comfortable to survive the survival period, extend the patient’s survival as much as possible, improve patient satisfaction, it is worth a wide range of clinical promotion application.